A clinical trial management system (CTMS) is a system used by Pharmaceutical and Biotechnology industries to manage clinical trials in clinical research. The system maintains and oversees the planning, performing and reporting functions, along with participant contact information, tracking deadlines and many more.
Europe Clinical Trials Market Segments Size & Growth:
Europe Clinical Trials market size is projected to reach approximately $XX billion by the end of 2024 with a CAGR of close to XX% from $XX billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Increasing incidences of chronic diseases, Rise in the number of clinical trials performed, Synchronization of Hospital Information System (HIS) with CTMS, Increase in R&D to implement localised research program. However, Huge cost of customised CTMS, Lack of qualified and skilled labour to handle CTMS, Data security issues are thereby hampering the market growth.
Europe Clinical Trials Market Segments Share:
Europe Clinical Trials Market is categorised into Phases which comprise of Phase I, Phase II, Phase III, Phase IV. By Design, The market is segmented into Observational Studies and Treatment Studies. By Geography, UK is projected to dominate the market with the most significant share.
Europe Clinical Trials Market Trends:
- PAREXEL International Corporation, a leading global biopharmaceutical services provider, announced that the Company has entered into a definitive agreement to acquire The Medical Affairs Company, LLC which is a leading provider of outsourced medical affairs services to the pharmaceutical, biotechnology, and medical device industries.
- To reduce cost pressures is to shift clinical trials to lower-cost areas. Globalizing clinical research provides CROs with an opportunity to run clinical trials efficiently and at a lower cost.
- Another trend that is fast evolving is to go paperless and increase the acceptance of electronic records. A novel drug application has hundreds and thousands of paper records. Adopting electronic records has made searching and analysis easier and also improved efficiencies of other initiatives to lower the costs of development and data management in clinical trials.
Europe Clinical Trials Market Research Report:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- The primary market players, such as
- Paraxel
- Omnicare
- Quotient Bioresearch
- Charles River
- Quintles
1.Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Increasing incidences of chronic diseases
4.1.2 Rise in the number of clinical trials performed
4.1.3 Synchronization of Hospital Information System (HIS) with CTMS
4.1.4 Increase in R&D to implement localised research programs
4.2 Restraints
4.2.1 Huge cost of customised CTMS
4.2.2 Lack of qualified and skilled labour to handle CTMS
4.2.3 Data security issues
4.3 Opportunities
4.3.1 Increasing Personalized Medicines
4.4 Challenges
4.4.1 Increasing Complexity of Trials
4.4.2 High on maintenance and operational costs
5. Europe Clinical Trials Market – By Phases
5.1 Phase I
5.2 Phase II
5.3 Phase III
5.4 Phase IV
6. Europe Clinical Trials Market- By Design
6.1 Observational Studies
6.1.1 Cohort Study
6.1.1.1 Time-Series Cohort
6.1.1.2 Retrospective Cohort
6.1.1.3 Prospective Cohort
6.1.2 Ecological Study
6.1.3 Cross Control Study
6.1.4 Case-Control Study
6.2 Treatment Studies
6.2.1 Randomized Control Trial
6.2.1.1 Double-Blind Randomized Trial
6.2.1.2 Non-Blind Trial
6.2.1.3 Single Blind Randomized Trial
6.2.2 Non-Randomized Clinical Trial
6.2.3 Adaptive Clinical Trial
7. Europe Clinical Trials Market– By Country
7.1.Introduction
7.2.France
7.3. Germany
7.4. The United Kingdom
7.5 Italy
7.6 Spain
7.7 Rest of Europe
8. Company Profiles
8.1 Paraxel
8.2 Accovion
8.3 Pharmnet
8.4 Quotient Bioresearch
8.5 ICON Plc
8.6 Chiltern
8.7 Omnicare
8.8 PPD
8.9 Kendle
8.10 Quintles
8.11 Charles River
9. Europe Clinical Trials Market– Competitive Landscape
9.1 Market Share Analysis
9.2 Strategies Adopted by top companies
9.3 Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1 Insights of Industry Experts
10.2 Investment Opportunities
10.3 Analyst Opinion
11. Appendix
11.1 List of Tables
11.2 List of Figures
